Abstract: The present invention relates to a method of production of a paper fibre composition, comprising the steps of: a) Providing a vessel, b) Providing Na2S03 in the range of 12-122 kg/bdt combined with NaOH in the range of 0-97 kg/bdt, or NaHSO3 in the range of 10-100 kg/bdt combined with NaOH in the range of 10-100 kg/bdt to said vessel, c) Providing wood, preferably softwood chips to said vessel for pre-treatment, d) Providing heat and pressure to said vessel in order be able control the vessel to have a temperature T comprised in the range of 160° C.-184° C.

Abstract: The present invention relates to a microemulsion comprising: 1-98 wt % of at least one polar lipid selected from polyglycerol fatty acid esters; 1-98 wt % of at least one emollient, not being a polyglycerolfatty acid ester; 0.1-3 wt % of at least one polar solvent; and 0-10 wt % of a surfactant, not being a polyglycerol fatty acid ester. The present invention further relates to said microemulsion for use as a medicament, and for use in the treatment and prevention of dry mucosa or prevention of airborne particles reaching topical mucosal membranes of a mammal. The present invention also relates to a liquid composition comprising said microemulsion, and an applicator device comprising said microemulsion.

Abstract: The present invention relates to a composition comprising at least one mono-glyceride chosen from glyceryl monocaprylate, glyceryl monolaurate and glyceryl monomyristate, and hydrophilic solvent, having a liquid crystalline lamellar structure at a temperature of above about 37° C., a solid crystalline lamellar structure below about 30° C. and a transformation of said solid and liquid crystalline lamellar structures at from about 30° C. to about 37° C., for use in treatment of cuts and wounds, said composition providing a moisturizing effect of said injury or wound, for reducing scab formation and promote healing in connection with injuries or wounds.

Abstract: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-I infection or HSV-2 infection are provided.

Abstract: A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about 45 to 750° C. The release modifier comprises a fatty alcohol, a fatty alcohol glycol ether, a fatty acid alkyl ester, a fatty acid glycerol ester, or a fatty acid sorbitane ester, having a hydrocarbon chain containing 12 to 18 carbon atoms and having a melting point of about ?10 to 400° C. Use of such a composition for the treatment and/or prophylaxis of a dermal or mucosal disorder, preferably an anorectal disorder associated with high anal pressure or anal sphincter spasm.

Abstract: The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least one of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower alcohols, and iso-form alcohols; wherein at least one of the penetration enhancing agents is selected from the group consisting of aliphatic diols and triols; and wherein the components are present in a non-aqueous solvent system. A preferred topical composition comprises the active substance imiquimod and the penetration enhancing agents isopropyl myristate and propylene glycol.

Abstract: A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about 45 to 750° C. The release modifier comprises a fatty alcohol, a fatty alcohol glycol ether, a fatty acid alkyl ester, a fatty acid glycerol ester, or a fatty acid sorbitane ester, having a hydrocarbon chain containing 12 to 18 carbon atoms and having a melting point of about ?10 to 400° C. Use of such a composition for the treatment and/or prophylaxis of a dermal or mucosal disorder, preferably an anorectal disorder associated with high anal pressure or anal sphincter spasm.

Abstract: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided.